title: Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma.
authors.affiliation: Istituto Regina Elena, Roma, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Calabresi
authors.forename: M
authors.initials: M
authors.lastname: Aapro
authors.forename: D
authors.initials: D
authors.lastname: Becquart
authors.forename: L
authors.initials: L
authors.lastname: Dirix
authors.forename: J
authors.initials: J
authors.lastname: Wils
authors.forename: A
authors.initials: A
authors.lastname: Ardizzoni
authors.forename: B
authors.initials: B
authors.lastname: Gerard
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000209:etiology / Q000556:secondary; D004341:Drug Evaluation; D005060:Europe; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000627:therapeutic use* / Q000633:toxicity; D009943:Organophosphorus Compounds / Q000627:therapeutic use* / Q000633:toxicity; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D009943:Organophosphorus Compounds; C054368:fotemustine